InvestSMART

Argenica Therapeutics Limited (ASX:AGN)

ALERT: Price-sensitive ASX Announcement for AGN
Current share price for AGN : $0.195 -0.075 (-27.78%)+
Announcement
Release
11 Dec 2025 9:11AM
Price at Release
$0.270
Full Release
download
Summary
Argenica Therapeutics Limited, an Australian biotechnology company, has announced significant results from an AI-driven reanalysis of its Phase 2 trial for ARG-007, a neuroprotective peptide aimed at reducing brain tissue death in stroke patients. The analysis confirmed the efficacy of ARG-007 in improving outcomes for severe acute ischaemic stroke patients, who have the greatest need for neuroprotection due to poorer outcomes post-thrombectomy. The study utilized Brainomix 360's AI tool to standardize stroke severity assessment, which reduced variability in patient selection and outcomes. The trial showed statistically significant improvements in follow-up infarct volume and functional outcomes as measured by the NIH Stroke Scale and modified Rankin Scale. Argenica plans to use these findings to advance to a Phase 2b trial, focusing on optimizing inclusion criteria around stroke severity to maximize efficacy.
Key Points
  • ARG-007 showed significant improvement in severe stroke patients.
  • AI tools were used to standardize stroke severity assessment.
  • Efficacy confirmed with statistically significant results.
  • Potential for ARG-007 to improve outcomes in severe strokes.
  • Plans for a Phase 2b trial focusing on severe stroke patients.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.